Details of the Drug

General Information of Drug (ID: DMH7MUV)

Drug Name
Zalcitabine
Synonyms
zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; ddC; Cytidine, 2',3'-dideoxy-; Zalcitibine; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; 2,3-dideoxycytidine; NSC 606170; UNII-6L3XT8CB3I; CCRIS 692; HSDB 7156; C9H13N3O3; Ro-24-2027/000; Ro 24-2027/000; CHEMBL853; BRN 0654956; 6L3XT8CB3I; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; WREGKURFCTUGRC-POYBYMJQSA-N; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; MFCD00012188; DdC; DdCyd; D 5782; DDC (DDC); DdC & Interferon alpha; DdC & sCD4; DdC (Antiviral); Hivid (TN); Hivid(TM); Interferon AD + ddC; KS-1130; SRI-7707; Beta-D-DDC; DS-4152 & ddC; DdC & GM-CSF; DdC & IFN-alpha; DdC & NP (from PHCA or HSA); PC-SOD & ddC; Zalcitabine [USAN:INN:BAN]; Hivid, Dideoxycytidine, NSC 606170, Zalcitabine; Zalcitabine (JAN/USP/INN); Beta-D-2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy & Interferon alpha; Sulfated polysaccharide-peptidoglycan DS-4152 & 2',3'-Dideoxycytidine; Cytidine, 2',3'-dideoxy-& Colony-stimulating factor; Beta-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor; Lecithinized superoxide dismutase & beta-D-2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon-alpha; 2',3'-Dideoxycytidine & Nanoparticles (from human serum albumin or polyhexylcyanoacrylate); 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; DdC
Indication
Disease Entry ICD 11 Status REF
Human immunodeficiency virus infection 1C62 Approved [1], [2]
Therapeutic Class
Anti-HIV Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 211.22
Topological Polar Surface Area (xlogp) -1.3
Rotatable Bond Count (rotbonds) 2
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Bioavailability
The bioavailability of drug is 80% [4]
Clearance
The drug present in the plasma can be removed from the body at the rate of 5.6 mL/min/kg [5]
Elimination
65% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 2 hours [5]
Metabolism
The drug is metabolized via the hepatic [4]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1522 micromolar/kg/day [6]
Unbound Fraction
The unbound fraction of drug in plasma is 0.96% [5]
Vd
The volume of distribution (Vd) of drug is 0.304-0.734 L/kg [7]
Water Solubility
The ability of drug to dissolve in water is measured as 76.4 mg/mL [3]
Chemical Identifiers
Formula
C9H13N3O3
IUPAC Name
4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
Canonical SMILES
C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N
InChI
InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1
InChIKey
WREGKURFCTUGRC-POYBYMJQSA-N
Cross-matching ID
PubChem CID
24066
ChEBI ID
CHEBI:10101
CAS Number
7481-89-2
DrugBank ID
DB00943
TTD ID
D0Z9QR
VARIDT ID
DR00175
INTEDE ID
DR1724
ACDINA ID
D01531

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human immunodeficiency virus Reverse transcriptase (HIV RT) TT84ETX POL_HV1B1 Inhibitor [8], [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 8 (ABCC11) DTWN7FC ABCCB_HUMAN Substrate [10]
Organic anion transporter 1 (SLC22A6) DTQ23VB S22A6_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [12]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [12]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Substrate [12]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [12]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [12]
Cytochrome P450 3A43 (CYP3A43) DEO1IE3 CP343_HUMAN Substrate [12]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Zalcitabine
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Cobicistat DM6L4H2 Moderate Decreased metabolism of Zalcitabine caused by Cobicistat mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [73]
Etravirine DMGV8QU Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Etravirine. Human immunodeficiency virus disease [1C60-1C62] [74]
Coadministration of a Drug Treating the Disease Different from Zalcitabine (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [73]
Bedaquiline DM3906J Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [75]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Zalcitabine and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [76]
Eribulin DM1DX4Q Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Eribulin. Breast cancer [2C60-2C6Y] [74]
Ixabepilone DM2OZ3G Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Ixabepilone. Breast cancer [2C60-2C6Y] [74]
Cabazitaxel DMPAZHC Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Cabazitaxel. Breast cancer [2C60-2C6Y] [74]
Trastuzumab Emtansine DMU1LXS Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Trastuzumab Emtansine. Breast cancer [2C60-2C6Y] [74]
Atorvastatin DMF28YC Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Atorvastatin. Cardiovascular disease [BA00-BE2Z] [74]
Polatuzumab vedotin DMF6Y0L Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Polatuzumab vedotin. Diffuse large B-cell lymphoma [2A81] [74]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Cannabidiol. Epileptic encephalopathy [8A62] [77]
Colchicine DM2POTE Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Colchicine. Gout [FA25] [74]
Isoniazid DM5JVS3 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Isoniazid. HIV-infected patients with tuberculosis [1B10-1B14] [74]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Brentuximab vedotin. Hodgkin lymphoma [2B30] [74]
Fluvastatin DM4MDJY Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Fluvastatin. Hyper-lipoproteinaemia [5C80] [74]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Zalcitabine and Mipomersen. Hyper-lipoproteinaemia [5C80] [78]
Rosuvastatin DMMIQ7G Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Rosuvastatin. Hyper-lipoproteinaemia [5C80] [74]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Zalcitabine and Teriflunomide. Hyper-lipoproteinaemia [5C80] [79]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Zalcitabine and BMS-201038. Hyper-lipoproteinaemia [5C80] [80]
Hydralazine DMU8JGH Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Hydralazine. Hypertension [BA00-BA04] [74]
Auranofin DMWE2N4 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Auranofin. Inflammatory arthropathy [FA2Z] [74]
Nelarabine DMB6VEG Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Nelarabine. Leukaemia [2A60-2B33] [74]
Crizotinib DM4F29C Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Crizotinib. Lung cancer [2C25] [74]
Hydroxychloroquine DMSIVND Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Hydroxychloroquine. Malaria [1F40-1F45] [74]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [81]
Fludarabine DMVRLT7 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Fludarabine. Malignant haematopoietic neoplasm [2B33] [74]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Idelalisib. Mature B-cell leukaemia [2A82] [82]
Ponatinib DMYGJQO Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Ponatinib. Mature B-cell lymphoma [2A85] [74]
Ipilimumab DMJTIYK Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Ipilimumab. Melanoma [2C30] [74]
Carfilzomib DM48K0X Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Carfilzomib. Multiple myeloma [2A83] [74]
Thalidomide DM70BU5 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Thalidomide. Multiple myeloma [2A83] [74]
Elotuzumab DMEYHG9 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Elotuzumab. Multiple myeloma [2A83] [74]
Orlistat DMRJSP8 Moderate Altered absorption of Zalcitabine caused by Orlistat. Obesity [5B80-5B81] [83]
Carboplatin DMG281S Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Carboplatin. Ovarian cancer [2C73] [74]
Levodopa DMN3E57 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Levodopa. Parkinsonism [8A00] [74]
Tocilizumab DM7J6OR Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Tocilizumab. Rheumatoid arthritis [FA20] [74]
Golimumab DMHZV7X Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Golimumab. Rheumatoid arthritis [FA20] [74]
Leflunomide DMR8ONJ Major Increased risk of hepatotoxicity by the combination of Zalcitabine and Leflunomide. Rheumatoid arthritis [FA20] [79]
Docetaxel DMDI269 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Docetaxel. Solid tumour/cancer [2A00-2F9Z] [74]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Zalcitabine and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [77]
Taxol DMUOT9V Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Taxol. Solid tumour/cancer [2A00-2F9Z] [74]
Pomalidomide DMTGBAX Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Pomalidomide. Systemic sclerosis [4A42] [74]
Amiodarone DMUTEX3 Moderate Increased risk of peripheral neuropathy by the combination of Zalcitabine and Amiodarone. Ventricular tachyarrhythmia [BC71] [74]
⏷ Show the Full List of 42 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Polyethylene glycol 4000 E00654 Not Available Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
⏷ Show the Full List of 7 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Zalcitabine 0.375mg tablet 0.375mg Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4828).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 BDDCS applied to over 900 drugs
4 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
8 A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
9 Current use of anti-HIV drugs in AIDS. J Antimicrob Chemother. 1993 Jul;32 Suppl A:133-8.
10 MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. J Biol Chem. 2003 Aug 8;278(32):29509-14.
11 Interaction of zalcitabine with human organic anion transporter 1. Pharmazie. 2006 May;61(5):491-2.
12 Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet. 1997 Mar;32(3):194-209.
13 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
14 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
15 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
16 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
17 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
18 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
19 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
20 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
21 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
22 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
23 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
24 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
25 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
26 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
27 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
28 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
29 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
30 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
31 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
32 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
33 Drug Interactions Flockhart Table
34 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
35 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
36 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
37 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
38 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
39 The role of cytochrome P450 3A (CYP3A) isoform(s) in oxidative metabolism of testosterone and benzphetamine in human adult and fetal liver. J Steroid Biochem Mol Biol. 1993 Jan;44(1):61-7.
40 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
41 Prediction of cytochrome P450 3A inhibition by verapamil enantiomers and their metabolites. Drug Metab Dispos. 2004 Feb;32(2):259-66.
42 The role of human cytochrome P450 enzymes in the formation of 2-hydroxymetronidazole: CYP2A6 is the high affinity (low Km) catalyst. Drug Metab Dispos. 2013 Sep;41(9):1686-94.
43 Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
44 Tamoxifen inhibits cytochrome P450 2C9 activity in breast cancer patients. J Chemother. 2006 Aug;18(4):421-4.
45 Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98.
46 Drug-drug interactions with imatinib: an observational study. Medicine (Baltimore). 2016 Oct;95(40):e5076.
47 Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos. 2000 Feb;28(2):125-30.
48 New insights into the structural features and functional relevance of human cytochrome P450 2C9. Part I. Curr Drug Metab. 2009 Dec;10(10):1075-126.
49 A potential role for the estrogen-metabolizing cytochrome P450 enzymes in human breast carcinogenesis. Breast Cancer Res Treat. 2003 Dec;82(3):191-7.
50 A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
51 Cytochrome P450 enzyme activity and protein expression in primary porcine enterocyte and hepatocyte cultures. Xenobiotica. 2000 Jan;30(1):27-46.
52 Rifampin markedly decreases plasma concentrations of praziquantel in healthy volunteers. Clin Pharmacol Ther. 2002 Nov;72(5):505-13.
53 Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica. 2003 Mar;33(3):265-76.
54 cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. Mol Pharmacol. 2001 Feb;59(2):386-92.
55 The anti-influenza drug oseltamivir exhibits low potential to induce pharmacokinetic drug interactions via renal secretion-correlation of in vivo and in vitro studies. Drug Metab Dispos. 2002 Jan;30(1):13-9.
56 Transport of aminopterin by human organic anion transporters hOAT1 and hOAT3: Comparison with methotrexate. Drug Metab Pharmacokinet. 2010;25(2):163-9.
57 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
58 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
59 Expression levels of renal organic anion transporters (OATs) and their correlation with anionic drug excretion in patients with renal diseases. Pharm Res. 2004 Jan;21(1):61-7.
60 Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007 Dec;35(12):2166-76.
61 Apical expression or expression in a non polarized cell of hOAT1 inverses regulation by epidermal growth factor (EGF) as compared to basolateral hOAT1. Cell Physiol Biochem. 2004;14(3):177-86.
62 Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs. Nucleosides Nucleotides Nucleic Acids. 2001 Apr-Jul;20(4-7):641-8.
63 ABCC11/MRP8 confers pemetrexed resistance in lung cancer. Cancer Sci. 2010 Nov;101(11):2404-10.
64 Human multidrug resistance protein 8 (MRP8/ABCC11), an apical efflux pump for steroid sulfates, is an axonal protein of the CNS and peripheral nervous system. Neuroscience. 2006;137(4):1247-57.
65 Tenofovir Disoproxil Fumarate Is a New Substrate of ATP-Binding Cassette Subfamily C Member 11. Antimicrob Agents Chemother. 2017 Mar 24;61(4). pii: e01725-16.
66 Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
67 HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
68 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
69 Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
70 Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
71 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
72 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
73 Cerner Multum, Inc. "Australian Product Information.".
74 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
75 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
76 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
77 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
78 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
79 Canadian Pharmacists Association.
80 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
81 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
82 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
83 MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".